Modeling Tumor Growth and Treatment Resistance Dynamics Characterizes Different Response to Gefitinib or Chemotherapy in Non‐Small Cell Lung Cancer

摘要: Differences in the effect of gefitinib and chemotherapy on tumor burden non-small cell lung cancer remain to be fully understood. Using a Bayesian hierarchical model size dynamics, we estimated rates growth treatment resistance for patients Iressa Pan-Asia Study study (NCT00322452). The following relationships characterize greater efficacy epidermal factor receptor (EGFR) positive tumors: Maximum drug is, decreasing order, EGFR-positive, EGFR-negative, EGFR-negative tumors; rate emergence increasing order: EGFR positive, while each is plausibly similar negative tumors, which are with less certainty. smaller EGFR-positive than resistant regardless treatment. can used compare effects dynamics among different drugs.